# Motixafortide

Source: https://onco.cc/drugs/motixafortide/  
OnCo record `motixafortide` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Motixafortide is an injection given with G-CSF before stem cell collection in people with multiple myeloma, approved in the United States in 2023, so that enough stem cells for an autologous transplant can be harvested in one or two sessions.

## Summary

BioLineRx's motixafortide blocks CXCR4 for far longer than plerixafor, the earlier drug of the class. In the GENESIS trial, a single dose with filgrastim let about 90 percent of multiple myeloma patients collect the target of six million CD34-positive cells per kilogram in up to two apheresis sessions, against about ten percent with filgrastim alone. The FDA approved it in September 2023, in combination with filgrastim, to mobilise haematopoietic stem cells for collection and autologous transplantation in patients with multiple myeloma. Injection site reactions and flushing are the common side effects. Ayrmid Pharma took over US commercial rights in 2024, and trials are exploring CXCR4 blockade with checkpoint inhibitors in pancreatic cancer.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-08
- Also known as: BL-8040; BKT140
- Tags: gap-fill; chembl-universe
- Brand: Aphexda
- Modality: CXCR4 antagonist peptide, subcutaneous injection
- Mechanism: A cyclic peptide that blocks the CXCR4 receptor, breaking the CXCL12 tether that holds stem cells in the marrow so they flood into the blood for collection.
- Approvals: US 2023: With filgrastim, to mobilise haematopoietic stem cells for collection and autologous transplantation in multiple myeloma

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Motixafortide
- Drugs@FDA NDA217159: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217159
- Label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=motixafortide
- Wikipedia: https://en.wikipedia.org/wiki/Motixafortide

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Filgrastim (G-CSF)](https://onco.cc/drugs/filgrastim/), [Plerixafor](https://onco.cc/drugs/plerixafor/)
- companies: [BioLineRx](https://onco.cc/companies/biolinerx/)
- trials: [Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients](https://onco.cc/trials/nct06514508/)

---
JSON: https://onco.cc/api/v1/entities/motixafortide.json